Chinese IVF Technology from Generation 1 to 3: Technical Principles and Applicable Populations Explained

AI Summary

Main Content Begins

Real Decision-Making Scenarios in the Clinic: How Doctors Choose the Technical Route

In reproductive medicine clinics, the doctor's decision on which generation of IVF technology to use is based on the patient's clear diagnosis, not the patient's preference or the generation number. Patients often come with information from their phones and ask, "Doctor, I want to go straight for Generation 3 IVF; I heard it has the highest success rate." This is a misconception that needs correction. Generation 3 IVF (PGT) is not more "advanced" than Generation 1 or 2; they each solve different problems.

The doctor's decision-making logic is as follows:
Female tubal blockage or ovulation disorder → Prioritize Generation 1 (IVF);
Male severe oligoasthenospermia or previous IVF fertilization failure → Prioritize Generation 2 (ICSI);
One partner has a chromosomal balanced translocation, monogenic genetic disease, or recurrent miscarriage → Only then consider Generation 3 (PGT).

This decision path is based on evidence-based medicine, not patient preference. The following sections analyze each technology from principles to practical application.

Generation 1, 2, and 3 IVF: Technical Principles and Core Differences

Chinese IVF technology from generation 1 to 3 is categorized based on the path to solving different reproductive obstacles, not iterative upgrades.

Why is there a misconception that "higher generation is better"? The main reason is that the naming convention easily reminds people of iterations of phones or computers. In reality, in the field of assisted reproduction, these three technologies are parallel. Generation 1 addresses female issues, Generation 2 addresses male issues, and Generation 3 addresses genetic issues. For a patient with tubal blockage, undergoing Generation 3 IVF does not improve the pregnancy rate but instead increases unnecessary risks and costs associated with embryo biopsy.

Comparison of Actual Procedures for Each Generation

Regardless of the generation, the first half of the procedure is essentially the same: ovarian stimulation → egg retrieval → in vitro fertilization. The differences appear at the fertilization stage and before embryo transfer.

Generation 1 (IVF) Procedure

• Ovarian Stimulation: Use Gn (gonadotropins) to stimulate the ovaries to develop multiple follicles, usually lasting 10-14 days.
• Egg Retrieval: Transvaginal ultrasound-guided puncture to retrieve eggs, the procedure takes about 15-20 minutes.
• In Vitro Fertilization: Place processed sperm and eggs in a culture dish for natural combination.
• Embryo Culture: Fertilized eggs develop in an incubator for 3-6 days to form cleavage-stage embryos or blastocysts.
• Transfer: Select 1-2 high-quality embryos for transfer into the uterus.
• Luteal Phase Support: Use progesterone medications to support the endometrium after transfer.

Generation 2 (ICSI) Procedure

• Ovarian Stimulation and Egg Retrieval: Same as Generation 1.
• Intracytoplasmic Sperm Injection: Under a microscope, an embryologist uses a micromanipulation needle to select a morphologically normal sperm and inject it directly into the egg cytoplasm.
• Subsequent Culture and Transfer: Same as Generation 1.

Key Prerequisite for ICSI: Usable sperm must be available from the male partner. For patients with obstructive azoospermia, sperm can be obtained via epididymal or testicular aspiration.

Generation 3 (PGT) Procedure

• Ovarian Stimulation, Egg Retrieval, Fertilization: Choose IVF or ICSI based on the male partner's condition (ICSI is often used to avoid sperm DNA contamination).
• Blastocyst Culture: Embryos must be cultured to the blastocyst stage (day 5-6) for biopsy.
• Embryo Biopsy: Create a hole in the zona pellucida and remove 3-5 trophectoderm cells for genetic analysis.
• Genetic Testing: Use technologies such as NGS, aCGH, or SNP array to detect chromosomal copy number variations or single gene mutations.
• Frozen Embryo Transfer: After results are obtained, select embryos that are chromosomally normal or do not carry the pathogenic gene for frozen-thawed transfer.
• Prenatal Diagnosis: After pregnancy, amniocentesis or NIPT is recommended to verify the test results.

PGT Requires Extra Time: From egg retrieval to obtaining test results usually takes 2-4 weeks, so only frozen embryo transfer is possible in this cycle.

Impact of Age on Technology Selection for Each Generation

Age is a core variable affecting egg and sperm quality but does not directly determine the choice of technology generation. However, age influences the doctor's recommendation for PGT.

The older the patient, the more likely the doctor will recommend PGT-A for screening chromosomally normal embryos, but this is contingent on obtaining a sufficient number of blastocysts. For older women with very low AMH and difficulty retrieving eggs, PGT may not be the optimal choice.

Differences in Technology Implementation Across Reproductive Centers

In China, institutions performing IVF technology must obtain approval from health authorities. Generation 1 and 2 IVF technologies are relatively common, but Generation 3 (PGT) has stricter qualification requirements.

• Generation 1 and 2 IVF: Most provincial and municipal reproductive centers can perform these, with a high level of technical maturity.
• Generation 3 (PGT): Requires a genetics laboratory, embryo biopsy technology, and genetic counseling capabilities. Currently, only about 80-100 institutions nationwide are approved to perform PGT, mainly in large teaching hospitals and provincial maternal and child health hospitals.
• Differences in Laboratory Standards: Embryo culture conditions (incubators, air quality, operational experience) vary between centers, directly affecting blastocyst formation rates and biopsy success rates.
• Genetic Testing Platforms: PGT institutions use different testing platforms (NGS, aCGH, SNP array) and testing scopes (whether covering all chromosomes, whether testing for single gene disorders).

When choosing a reproductive center, patients should confirm that the institution has the appropriate qualifications for the technology and understand its embryology laboratory quality control indicators (e.g., blastocyst formation rate, freeze-thaw survival rate, pregnancy rate, etc.).

Details Most Easily Overlooked in Technology Selection

In daily consultations, several details are often overlooked by patients but have a substantial impact on treatment outcomes.

• PGT cannot detect all genetic diseases: It can only detect known pathogenic genes or chromosomal structural abnormalities. Its detection capability is limited for de novo mutations, polygenic diseases, and complex genetic disorders.
• Prenatal diagnosis is still required after PGT: Embryo biopsy has limitations (mosaicism, testing errors). Verification via amniocentesis or NIPT is recommended after pregnancy.
• ICSI is not a "more advanced" fertilization method: For patients with normal sperm parameters, there is no significant difference in fertilization rates between ICSI and IVF, and ICSI carries theoretical genetic risks (e.g., introducing sperm DNA damage into the egg).
• Carriers of chromosomal balanced translocations: Require PGT-SR (structural rearrangement testing), not standard PGT-A. The strategies and platforms for these two tests differ.
• Causes of recurrent implantation failure are complex: Not solely due to embryonic chromosomal issues; factors include endometrial receptivity, immune factors, coagulation function, etc. PGT cannot solve all problems.

Frequently Asked Questions in the Clinic

The following questions are most frequently asked in reproductive medicine clinics and are the ones patients most need clear answers to.

Question 1: Which generation has the highest success rate: Generation 1, 2, or 3?
Success rate depends on the patient's specific etiology and age, not the technology generation. For a young woman with tubal factor infertility, the live birth rate with IVF can reach 50-60%; for a man with severe oligoasthenospermia, the fertilization rate with ICSI can reach 70-80%; for a patient with a chromosomal balanced translocation, PGT can significantly reduce the miscarriage rate. Discussing success rates without considering the etiology is meaningless.

Question 2: Can sex selection be done with Generation 3 IVF?
In China, non-medical sex selection is strictly prohibited. PGT can be used for sex-linked genetic diseases (such as hemophilia, DMD, etc.) to screen for embryos that do not carry the pathogenic gene, but this is a medical necessity, not sex selection.

Question 3: Why doesn't the doctor recommend Generation 3 IVF for me?
If the patient's diagnosis does not meet the indications for PGT (e.g., simple tubal blockage, normal male sperm parameters, no genetic disease risk), the doctor will not recommend PGT. This is because PGT not only increases cost and time but also carries risks of biopsy, embryo loss, and testing uncertainty.

Question 4: What preparations are needed for PGT?
It requires karyotype analysis of both partners, genetic counseling, and relevant genetic testing (e.g., for thalassemia, hemophilia, etc.). Additionally, it is necessary to confirm that the reproductive center has PGT qualifications and to understand the testing platform and cycle.

Question 5: How long does a PGT cycle take?
From ovarian stimulation to the opportunity for transfer, it usually takes 2-3 months. This includes about 2 weeks for ovarian stimulation, 1-2 weeks for embryo culture and biopsy, 2-4 weeks for genetic testing, followed by scheduling the frozen embryo transfer.

Question 6: What are the risks of PGT?
Main risks include: the biopsy procedure may cause damage to the embryo (probability about 1-2%); test results may show mosaicism or be inconclusive; no normal embryos may be available for transfer after testing; PGT cannot 100% rule out the risk of genetic disease.

⚠️ This content is based on the consensus of the assisted reproductive medicine industry (updated 2025) and is for informational purposes only. Specific diagnosis and treatment plans should be carried out under the guidance of a doctor at a reproductive center and do not constitute medical advice or a guarantee.